IL17A and psoriasis: Currently, biological agents, such as TNF-a inhibitors and antibodies against IL12/23 and IL17, are recommended as the first-line treatments for moderate-to-severe psoriasis, but some drawbacks including high cost, side effects, and drug resistance limit their applications.